433results about "Fibroblast growth factor" patented technology

The invention discloses application and a preparation method of exosome EGF-FGF-EXO containing double growth factors, the exosome EGF-FGF-EXO is uniform in particle size, high in loading efficiency and good in biological activity, the double growth factors comprise an epidermal growth factor EGF and a fibroblast growth factor FGF, and the epidermal growth factor EGF and the fibroblast growth factor FGF are added into the exosome EGF-FGF. The preparation method of the exosome EGF-FGF-EXO comprises preparation of an induced pluripotent stem cell (iPSC) exosome and loading of EGF-FGF, a recombinant epidermal growth factor (EGF) and a fibroblast growth factor (FGF) are loaded on the exosome from iPS-clone 12c, and the exosome product which has high biological activity and is used for treating nervous system diseases of neuroinflammation is prepared. The invention develops a brand new technical path for treatment of nervous system diseases, and in the fields of epilepsy, neurodegenerative diseases, brain injury and the like, the life quality of patients can be improved and important theoretical basis and technical support can be provided for precise medical treatment of nervous system diseases by precisely regulating and controlling neuroinflammation.

The invention discloses a preparation process for efficiently obtaining a high-purity and high-activity pig umbilical cord extract. Comprising the following steps: S1, cleaning a pig umbilical cord; s2, crushing the pig umbilical cord; s3, filtering the ground pig umbilical cord; s4, performing ultrasonic treatment on the buffer solution and the pig umbilical cord tissue; s5, carrying out centrifugation to extract a supernatant; the novel pig umbilical cord is adopted to extract the extract, so that the precipitation rate of the extract can be increased; the pig umbilical cord is treated through an enzymolysis method, so that connecting substances between cells in the pig umbilical cord can be damaged, cells in umbilical cord tissue can be conveniently ground and broken, the precipitation rate of the pig umbilical cord extract is increased, the cells of the pig umbilical cord cannot be damaged by using the enzymolysis method, and the activity of the cells is kept; and moreover, ultrasonic treatment is adopted, so that cells can be destroyed, the extract can be efficiently separated out, and the obtaining rate of the extract is increased.

The present invention relates to a peptide having anti-aging activity and a composition for skin regeneration or suppressing skin aging, comprising the peptide as an active ingredient. The peptide according to the present invention, comprising an amino acid sequence of SEQ ID NO: 1, has anti-aging activity and thus can be used as a raw material for a cosmetic product for skin regeneration or suppressing skin aging or as a raw material for a pharmaceutical product for preventing, ameliorating, or treating photoaging.

The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.

Provided are a GLP-1GIP analog, an FGF21 protein, a trifunctional protein, and use thereof. The trifunctional protein comprises the GLP-1 / GIP analog and the FGF21 protein. Further provided is use of the GLP-1 / GIP analog, the FGF21 protein, and the trifunctional protein in the preparation of a drug for preventing and / or treating diseases related to GLP-1, GIP, and / or FGF21. The provided GLP-1 / GIP analog, FGF21 protein, and trifunctional protein can synergistically regulate blood glucose and lipid levels in vivo, meet multiple needs in patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, promoting weight loss, ameliorating circulating lipid metabolism disorder, etc., and have better biological safety and tolerability and longer in vivo half-lives.

Described herein are methods of treating a disease, disorder or a condition associated with dry eye caused by a multifactorial disease of ocular surface, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a modified FGF-1 polypeptide.

The invention discloses a GLP-1 GIP analogue, an FGF21 protein, a three-function protein and an application thereof. The trifunctional protein comprises a GLP-1 / GIP analogue and an FGF21 (Fibroblast Growth Factor 21) protein. The invention also discloses application of the GLP-1 / GIP analogue, the FGF21 protein and the three-function protein in preparation of medicines for preventing and / or treating diseases related to GLP-1, GIP and / or FGF21. The GLP-1 / GIP analogue, the FGF21 protein and the three-function protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, meet multiple requirements of patients with type 2 diabetes for reducing blood sugar, relieving liver fatty degeneration, reducing weight, improving circulating lipid metabolism disorder and the like, and are better in biological safety and tolerance and longer in in-vivo half-life period.

A dual function protein is disclosed. The dual function protein may be prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin. The dual function protein has improved pharmacological efficacy, in vivo duration and protein stability. The dual function protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.

The present disclosure relates to methods of treating, preventing or managing cardiovascular and / or metabolic disorders selected from the group consisting of hypercholesteremia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes and obesity in a human subject in need thereof by administering a human FGF21 protein variant.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention relates to the technical field of gene engineering, and particularly discloses a coding sequence of a recombinant protein, the recombinant protein, a preparation method, a recombinant strain and application, and the coding sequence of the recombinant protein comprises a coding sequence shown as SEQ01 or SEQ03. Wherein the amino acid sequence of the recombinant protein is as shown in SEQ ID NO. 02 or SEQ ID NO. 04. The invention solves the problems of low expression level of vascular factors after spinal cord injury and limited number of blood vessels repaired and regenerated by conventional drug therapy in the conventional technology. The invention has the effect of promoting vascularization after spinal cord injury.

Methods of gene therapy are provided for treating or preventing age-related diseases or conditions by regulating one or more functional proteins associated with age-related diseases or conditions.

The invention provides recombinant escherichia coli for preparing soluble EC-SOD and application of the recombinant escherichia coli, and relates to the technical field of biological engineering. According to the present invention, SOD and KGF2 genes are connected by using a connecting peptide coding sequence containing a protease cleavage site, and are cloned to a pET28a expression vector; the pET28a expression vector is transformed into competent cells of escherichia coli BL21 (DE3), and recombinant escherichia coli is constructed. The obtained recombinant Escherichia coli can solve the problem that an inactive inclusion body is formed when EC-SOD is expressed in Escherichia coli. The method is suitable for preparing soluble EC-SOD.

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

Provided are use of FGF21 polypeptide, FGF21 fusion protein or dual-fusion protein of FGF21 polypeptide and GLP-1 or a functional variant thereof in the manufacture of a medicament for treating fatty liver-related diseases.

The present invention relates to a chemically modified adeno-associated virus (AAV), a method for preparing the same, and its use in gene therapy. The chemically modified AAV is preferably prepared by incubating the AAV with a chemical reagent having an N-substituted luminol moiety under conditions conducive to reaction of the chemical reagent with tyrosine residues exposed on the surface of the AAV capsid, preferably by electrochemical methods.

To provide: a method for producing a complicated peptide molecule, such as a dimeric peptide, in a simpler manner at lower cost compared with the conventional chemical synthesis methods; a dimeric peptide which comprises a specific short linker and has a satisfactory activity; and others.SOLUTION: A peptide molecule comprises: (I) a first physiologically active peptide portion; (II) a linker portion composed of 49 or less amino acid residues; and (III) a second physiologically active peptide portion located on the opposite side of the linker portion from the first physiologically active peptide portion, wherein the first physiologically active peptide portion and the second physiologically active peptide portion may be the same as or different from each other, and at least 90% of an amino acid sequence of the linker portion is composed of amino acid residues selected from alanine (A), proline (P), and serine (S).SELECTED DRAWING: None

The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.

The present invention belongs to the field of biopharmaceuticals, and particularly relates to a multi-domain active protein for treating metabolic diseases. The multi-domain active protein has a structural formula as shown in Formula I: A-L a -F-L b -B. Compared with the prior art, the multi-domain active protein of the present invention has a long half-life and supports a once-weekly dosing frequency; the GLP-1R agonist activity of the multi-domain active protein is increased by more than 200 times at most; the multi-domain active protein has good stability in vivo and in vitro and low immunogenicity; since no unnatural amino acids need to be introduced and no chemical synthesis and cross-linking steps are involved, it can be prepared by a recombinant method, greatly simplifying the preparation process.

Provided herein are polynucleotides comprising a coding sequence for expression of a fibroblast growth factor 21 (FGF21) pathway activating agent. Also provided are vectors, recombinant viral genomes, and recombinant virus compositions comprising said polynucleotides, as well as associated methods.

A long-acting FGF21 derivative, specifically relating to an FGF21 derivative comprising an FGF21 mutant protein and a fatty acid chain. The FGF21 derivative, which is obtained by coupling the fatty acid chain to a cysteine residue at position 172 of an FGF21 protein by means of a linker, has relatively high FGF21 activity, and has a better weight loss effect in model mice. The FGF21 mutant protein not only retains the activity of mature FGF21, but also has significantly improved stability in serum.

The invention relates to a thermostable FGF10 polypeptide possessing FGF10 activity and having or comprising at least 85% sequence identity to SEQ ID NO:3 that has or comprises an amino acid sequence from Ser69 to Ser208 of SEQ ID NO:1, or to SEQ ID NO:5 that has or comprises an amino acid sequence from Leu40 to Ser208 of SEQ ID NO:1, or the fragments thereof, comprising at least an amino acid substitution L152F. Preferably, any of amino acid substitutions V123I, Q175E, and N181D can be further included. The invention further discloses the use of subjected thermostable FGF10 polypeptides in regenerative medicine or other related medical applications or cosmetics. Further, it discloses a culture medium comprising subjected thermostable FGF10 polypeptides suitable for proliferation and differentiation of the human embryonic stem cells or formation and differentiation of spheroids and organoids.

The present invention provides a kit and method for breeding wool traits of Qinghai Tibetan sheep, belonging to the field of SNP detection. The present invention provides a screening kit for sheep with long braid length, which includes a reagent for detecting the 117456167th site of chromosome 6 of the sheep reference genome. The present invention also provides a screening method for sheep with long braid length. The kit and method of the present invention effectively screen sheep with long braid length, quickly determine sheep populations with excellent braid length traits, are of great significance for improving the wool performance of Tibetan sheep, and have very good application prospects.

Compositions, methods and treatment regimens for mutant fibroblast growth factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.

Provided are fibroblast growth factor 4 (FGF4) and Fgfr1 binding ligands for treating metabolic diseases, a treatment method using the fibroblast growth factor 4 (FGF4) and Fgfr1 binding ligands, and use of the fibroblast growth factor 4 (FGF4) and Fgfr1 binding ligands in preparing medicines.

Methods of gene therapy are provided for treating or preventing age-related diseases or conditions by regulating one or more functional proteins associated with age-related diseases or conditions.

The present invention relates to an isolated polypeptide, or a functional fragment thereof, having at least 85% sequence identity to SEQ ID NO: 12, comprising an amino acid substitution at position C113, preferably C113A.5

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

A production method for a cell aggregate containing a retinal tissue having a layer structure, the method comprising performing suspension culturing or adhesive culturing of a dispersed retinal cell population in a medium containing a Wnt signal transduction pathway acting substance, wherein the retinal cell population includes at least one type of cells selected from the group consisting of retinal precursor cells and photoreceptor precursor cells.